Antimicrobial activities of some synthesized 1-(3-(2-methylphenyl)-4-Oxo-3H-quinazolin-2-yl-4-(substituted)thiosemicarbazide derivatives
- 作者: Alagarsamy V.1, Anjana G.2, Sulthana M.1, Parthiban P.1, Solomon V.1,3
-
隶属关系:
- Medicinal Chemistry Research Laboratory
- Department of Pharmaceutical Chemistry
- Faculty of Pharmacy, the University of Sydney
- 期: 卷 42, 编号 3 (2016)
- 页面: 332-339
- 栏目: Article
- URL: https://journals.rcsi.science/1068-1620/article/view/227978
- DOI: https://doi.org/10.1134/S106816201603002X
- ID: 227978
如何引用文章
详细
The substituted thiosemicarbazide moiety was placed at the C-2 position and 2-methylphenyl group at N-3 position of quinazoline ring and obtained compounds were tested for their antitubercular activities and antibacterial activities against selected gram-positive and gram-negative bacteria. The target compounds 1-(3-(2-methylphenyl)-4-oxo-3H-quinazolin-2-yl)-4-(substituted) thiosemicarbazides were obtained by the reaction of 2-hydrazino-3-(2-methylphenyl) quinazolin-4(3H)-one with different dithiocarbamic acid methyl ester derivatives. All synthesized compounds were also screened for their antimicrobial activity against selective gram-positive and gram-negative bacteria by agar dilution method. Among the series, 1-[3-(2-methylphenyl)-4-oxo-3H-quinazolin-2-yl]-4-[4-chlorophenyl]-thiosemicarbazide exhibited the most potent activity against S. typhi, E. coli, and B. subtilis, while 1-[3-(2-methylphenyl)-4-oxo-3H-quinazolin-2-yl]-4-[4-nitrophenyl]-thiosemicarbazide was the most potent against E. coli, B. subtilis, P. aeruginosa, S. typhi, and S. flexneri. These two compounds exhibited the antitubercular activity at the minimum concentration (3 μg/mL) that offered potential for further optimization and development of new antitubercular agents. The obtained results demonstrated promising antimicrobial and antitubercular activities of the synthesized quinazoline compounds which could be used as new scaffolds for improving their antimicrobial activity.
作者简介
V. Alagarsamy
Medicinal Chemistry Research Laboratory
编辑信件的主要联系方式.
Email: drvalagarsamy@gmail.com
印度, Gr. Hyderabad, 502294
G. Anjana
Department of Pharmaceutical Chemistry
Email: drvalagarsamy@gmail.com
印度, Thiruvananthapuram, 695575
M. Sulthana
Medicinal Chemistry Research Laboratory
Email: drvalagarsamy@gmail.com
印度, Gr. Hyderabad, 502294
P. Parthiban
Medicinal Chemistry Research Laboratory
Email: drvalagarsamy@gmail.com
印度, Gr. Hyderabad, 502294
V. Solomon
Medicinal Chemistry Research Laboratory; Faculty of Pharmacy, the University of Sydney
Email: drvalagarsamy@gmail.com
印度, Gr. Hyderabad, 502294; Sydney, NSW, 2006